SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending due to a surge in investor interest, fueled by a recent Air Force contract and non-dilutive funding, which validates the company's quantum computing roadmap. The community is actively discussing the stock's potential, comparing it to other high-growth tech stocks and debating whether it's overvalued. Some traders are pointing to a potential short squeeze, while others highlight the long-term potential of quantum computing and the company's partnerships.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel $INTC is trending as chatter swirls around a potential investment from Apple $AAPL as part of Intel's turnaround efforts, fueled by a recent Bloomberg report. Community members are speculating about the implications of Apple taking a stake and potential collaborations, while some express skepticism, recalling past struggles. The news arrives amid broader discussions of government support for US chip manufacturing and Intel's role in the AI landscape.

Lithium Americas Corp. engages in the development of the Thacker Pass project. It is focused on advancing Thacker Pass to production it is located in northern Nevada. The company was founded on January 23, 2023 and is headquartered in Vancouver, Canada.

Lithium Americas Corp (NewCo)

Lithium Americas Corp

Lithium Americas ($LAC) is trending due to reports of the Trump administration potentially taking an equity stake in the company linked to a $2.26 billion Energy Department loan, sparking significant community discussion around potential government backing and the future of lithium supply. The news has triggered a surge in the stock price as investors speculate on the implications for the company's Thacker Pass project and the broader lithium sector, with some comparing it to previous government investments in critical industries. Discussions also include potential dilution and off-take agreements.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure ($QURE) is trending following positive Phase I/II data for its Huntington's disease gene therapy, with analysts raising price targets and the community discussing its potential for accelerated FDA approval. Bullish sentiment is fueled by the statistically significant slowing of disease progression, while some traders are wary of a potential offering or pullback. The stock's high short interest is adding to the volatility as traders debate whether to short the stock or ride the momentum.

TNF Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

TNF Pharmaceuticals Inc.

TNF Pharmaceuticals (TNFA) is trending as traders discuss its recent strategic shift towards quantum computing and a name change to Q/C Technologies, sparking both excitement and skepticism. Bullish sentiment centers on the potential of their exclusive rights to light-speed laser processing for cryptocurrency applications, while bears cite concerns about dilution and the company's history. The community is actively debating whether this pivot justifies the stock's increased volatility and potential for a short squeeze.

Astera Labs, Inc. is a global semiconductor company, which engages in the provision of hardware and software solutions for AI and cloud infrastructure applications to solve data, memory, and networking bottlenecks. It operates through the following geographical segments: Taiwan, China, United States, and Other. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

ALAB is trending due to a significant sell-off, with community members citing potential Intel/Nvidia competition and overvaluation concerns as possible catalysts; some suspect market manipulation. Despite strong YTD growth fueled by PCIe demand and a recent positive earnings report, investors are debating its sustainability amid competition from major players like AVGO and MRVL. Discussions include whether the drop is a buying opportunity or a sign of further declines.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

VKTX is trending amid speculation about a potential buyout or partnership, especially with other companies in the weight loss space being acquired. Community members are actively discussing potential suitors and the value of Viking's pipeline, citing positive trial data and a manageable tolerability profile. Some traders are eyeing technical indicators, while others are focused on upcoming presentations and potential catalysts.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

$UPST is trending amid a pullback, sparking a debate about its potential. Community members are discussing whether it's a buying opportunity for a short squeeze or if further downside is expected, particularly as it relates to rates. Some express frustration with its performance relative to other fintech stocks.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending amid debates about its valuation and future prospects, with discussions focusing on its lack of current revenue and potential for an offering. Community sentiment is divided, with some highlighting insider selling and regulatory hurdles, while others point to the company's potential role in powering AI data centers. The stock's significant gains over the past month have also spurred conversations around pullbacks and potential buying opportunities within the nuclear sector.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as the community discusses its recent price movement and potential breakout above the $15-$16 resistance level, with some pointing to a shift in market sentiment. The groundbreaking of the Georgia plant is also generating buzz, although some express concerns about cash burn and production timelines. Overall, the conversation is focused on whether Rivian can maintain its upward momentum and capitalize on upcoming catalysts like the R2 launch.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

United States Antimony Corp. (UAMY) reportedly said on Tuesday it has secured a five-year contract worth up to $245 million from the U.S. Defense Logistics Agency.According to a Reuters report, the company secured a sole-source contract to supply antimony metal ingots for the defense stockpile.Retail sentiment on the <a href="https://stocktwits.com/symbol/UAMY">stock</a> remained unchanged in the ‘extremely bullish’ territory, with message volumes at ‘high’ levels, according to data from Stocktwits. Shares of the company jumped over 21% in early trading on Tuesday.Since taking office, U.S. President Donald Trump has implemented multiple executive and policy measures to strengthen U.S. access to critical minerals as part of the country’s efforts to maintain national security and economic self-reliance. Reuters noted that Antimony, which is used in munitions, batteries, and military-grade compounds, was flagged as a vulnerability in the U.S. industrial base by defense officials.“It’s incredibly meaningful for all our employees to play such a strategic role in strengthening our nation's defense readiness," USAC CEO Gary C. Evans said, according to Reuters.The report noted that U.S. Antimony Corp operates North America’s only two antimony smelters and is positioned to begin immediate fulfillment from its domestic facilities. Reuters, citing the company, said that the first delivery order is expected this week.Shares of the company have jumped 322% this year and gained nearly 860% in the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/amazon-faces-ftc-in-trial-over-alleged-prime-enrollment/chDhMWHR357">Amazon Faces FTC In Trial Over Alleged Prime Enrollment Strategy: Report</a>

US Antimony Secures $245M Defense Contract Over Five Years: Report

According to a Reuters report, the company secured a sole-source contract to supply antimony metal ingots for the defense stockpile.

Equity

Strength Seen in Centrus Energy (LEU): Can Its 12.1% Jump Turn into More Strength?

Centrus Energy (LEU) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Strength Seen in Coeur Mining (CDE): Can Its 7.0% Jump Turn into More Strength?

Coeur Mining (CDE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

The broader market experienced mixed performance on Monday, with major indices showing volatility but ultimately closing higher. The Dow Jones Industrial Average gained 0.78%. The S&amp;P 500 rose 0.79%, and the Nasdaq Composite climbed 0.64%. However, all three major averages were in the red at one point during the trading session. Despite this, the stocks making moves on market news continued to captivate investors with their dynamic performances and strategic advancements. In this article, we will take a look at the 6 best stocks that were making moves on market news with their groundbreaking innovations and strategic advancements.Also Read: <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/stocks/biotech/quantum-biopharma-expands-reach-with-new-unbuzzd-launch-and-cutting-edge-ms-clinical-study/">This Low-Float Biotech Stock is making waves with an advanced MS diagnostic tool</a><a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/newsletter-sign-up/">Our email list eats first! Get exclusive alerts on explosive stock picks like AST SpaceMobile (NASDAQ: ASTS), which shot up +533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.</a><h3>1. Recursion Pharmaceuticals (RXRX)&nbsp;&nbsp;</h3>Market Cap as of April 15: $2.34 Billion&nbsp;&nbsp;Recursion Pharmaceuticals (NASDAQ: RXRX) is a clinical-stage biotechnology company that leverages artificial intelligence and automation to discover and develop novel therapeutics across a wide range of diseases.First Patient Dosed: Recursion Pharmaceuticals has recently announced the dosing of the first patient in its early-stage study of REC-3565 for treating relapsed or refractory B-cell lymphomas, which marks a significant clinical milestone.Unique Mechanism: REC-3565 has a unique mechanism of action that reduces the risk of drug-drug interactions and hyperbilirubinemia, making it potentially safer and more effective.Preclinical Success: Preclinical studies showed durable tumor regressions with REC-3565, both as monotherapy and in combination with a BTK inhibitor, which indicates strong clinical efficacy.Industry Collaborations: The company has partnerships with major pharmaceutical companies such as Roche, Bayer, Merck, and Sanofi, which provides it with additional resources and market access.FDA Policy Shift: The FDA has also announced to phase out some animal testing requirements for monoclonal antibodies, which benefits RXRX’s AI-driven platform.Stock Performance:Recursion Pharmaceuticals has shown strong weekly performance with a 45.26% gain. However, it has underperformed in the month and year, with declines of 15.69% and 31.43%, respectively.<h3>2. Certara (CERT)&nbsp;&nbsp;</h3>Market Cap as of April 15: $2.29 Billion&nbsp;&nbsp;Certara (NASDAQ: CERT) provides biosimulation software and technology-driven solutions to improve the drug development process, helping biopharma companies optimize clinical outcomes.Strong First Quarter Financial Results: On April 14, Certara reported preliminary first-quarter 2025 financial results.&nbsp; The company reported a 10% revenue growth to $106.0 million compared to the first quarter of 2024, with software revenue growing by 18% to $46.4 million.Bookings Growth: The company’s bookings increased by 12% to $118 million, with software bookings growing by 22% to 40.6 million.Adjusted EBITDA Growth: Adjusted EBITDA is expected to be in the range of $33 million to $35 million, representing a 13-20% growth compared to the first quarter of 2024.Reiteration of Full-Year Guidance: Certara reiterated its full-year 2025 guidance, projecting revenue in the range of $415 million to 425 million, an adjusted EBITDA margin of 30-32%, and adjusted diluted earnings per share of 42 to 46 cents.Stock Repurchase Authorization: The Board of Directors authorized a stock repurchase program of up to $100 million, reflecting confidence in the company’s strategy and financial performance.Non-Animal Navigator Launch: Certara launched its Non-Animal Navigator solution to help biopharmaceutical companies reduce reliance on animal testing by offering strategic regulatory advice, integrated preclinical development plans, and optimized AI-enabled modeling tools.Industry Adoption: The growing industry adoption of new approach methodologies (NAMs) like AI-enabled biosimulation supports Certara’s strategic focus and enhances its competitive position.Stock Performance:Certara has had a robust week with a 57.18% increase. However, it has faced losses over longer periods, including a 19.50% decline in performance year-to-date.<h3>3. United States Antimony (UAMY)&nbsp;&nbsp;</h3>Market Cap as of April 15: $377.72 Million&nbsp;&nbsp;United States Antimony (NYSEAMERICAN: UAMY) is involved in the mining, production, and sale of antimony and zeolite products, which are used in flame retardants, batteries, and chemical applications.Lease/Option Purchase Agreement: United States Antimony has executed a new lease/option purchase agreement with an experienced prospector in Wasilla, Alaska, for lands adjacent to existing leased and staked claims, with new claims and leases totaling 17,900 acres in the Fairbanks area and 3,840 acres near Stibnite Creek.Exploration Focus: Plans to begin high-grade stibnite exploration and mining operations in early May in the Fairbanks area. Management aims to extract antimony ore from its own mining claims in Alaska to Montana by Q3 2025.Antimony Production and Global Supply: China is the world’s top producer of antimony, but its output has been declining over the past decade, making it difficult to meet global needs without new sources. Furthermore, Antimony prices have surged due to China’s export ban, which began in December 2024.Montana Smelters: The company operates two smelters in Montana with capacities of 3,840tpa and 2,400tpa for antimony processing.Stock Performance:United States Antimony has demonstrated exceptional growth across various periods, including a strong weekly gain of 66.92%. It has also seen a remarkable year-over-year growth of 1,239.51%.&nbsp;Read Now: <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/stocks/tech/u-power-makes-waves-at-bangkok-motor-show-with-groundbreaking-battery-swap-demo/">Electric Vehicle Player Is Making Waves With Groundbreaking Battery Swapping Technology</a><a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/newsletter-sign-up/">Our email list eats first! Get exclusive alerts on explosive stock picks like AST SpaceMobile (NASDAQ: ASTS), which shot up +533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.</a><h3>4. Janover (JNVR)&nbsp;&nbsp;</h3>Market Cap as of April 15: $106.54 Million&nbsp;&nbsp;Janover (NASDAQ: JNVR) provides online platforms for commercial real estate and small business loans, connecting borrowers with lenders using data-driven digital solutions.New Treasury Strategy: Janover announced a new treasury policy on April 4, 2025, to accumulate crypto assets, starting with Solana (SOL). This strategy aligns with the company’s goal of providing investors economic exposure to SOL.Significant SOL Purchases: Janover made substantial purchases of Solana (SOL) tokens, totaling $21.2 million across three transactions. These purchases have brought the company’s total SOL holdings to 163,651.7.Staking and Revenue Generation: The company will begin staking its SOL position immediately, generating revenue while supporting the Solana network. Staking rewards are also planned to be reinvested, which will further enhance cryptoasset holdings.Recent Financing Round: Janover has also raised $42 million in a financing round from investors including Pantera Capital and Kraken. These funds are specifically allocated for acquiring digital assets.Stock Performance:Janover has seen explosive growth, with a week-over-week performance of 130.20% and a remarkable 1707.42% increase in the month.<h3>5. Skye Bioscience (SKYE)</h3>Market Cap as of April 15: $82.40 MillionSkye Bioscience (NASDAQ: SKYE) is a pharmaceutical company focused on developing cannabinoid-derived molecules to treat glaucoma and other diseases with unmet medical needs.Significant Weight Loss in Preclinical Study: On April 15, Skye Bioscience announced over 30% weight loss in a diet-induced obesity model when nimacimab was combined with tirzepatide, which showcases its strong efficacy and potential as a combination therapy.Comparable Efficacy to Monlunabant and Tirzepatide: Nimacimab alone achieved 23.5% weight loss, comparable to other leading obesity drugs like tirzepatide and monlunabant, which indicates robust monotherapy potential.Differentiated Mechanism: Nimacimab’s non-competitive allosteric binding to the CB1 receptor provides a differentiated mechanism compared to monlunabant and has potentially fewer neuropsychiatric side effects.Superior Potency in High Agonist Conditions: In vitro data showed nimacimab’s potency remained stable under high agonist conditions, while monlunabant’s effectiveness was significantly impacted, which indicates superior performance in disease states like obesity.Phase 2a Data: Top-line data from the Phase 2a CBeyond study is expected in late Q3/early Q4 2025, which will provide investors with near-term clinical validation of nimacimab’s efficacy.Focus on Metabolic Health: Skye’s focus on developing next-generation molecules for metabolic health disorders aligns with the growing demand for effective obesity treatments in the market.First-In-Class Therapeutic Potential: Nimacimab’s mechanism of action as a negative allosteric modulating antibody for CB1 inhibition positions it as a first-in-class therapeutic with clinical and commercial differentiation.Stock Performance:Skye Bioscience has had a mixed performance, with a significant weekly gain of 143.32% but a modest monthly gain of only 15.41%.<h3>6. Aerovate Therapeutics (AVTE)</h3>Market Cap as of April 15: $79.12 MillionAerovate Therapeutics (NASDAQ: AVTE) is a biotechnology company developing inhaled therapies for rare cardiopulmonary diseases, with a lead candidate targeting pulmonary arterial hypertension.Expected Cash Dividend: Aerovate Therapeutics expects to declare a cash dividend in the range of $67.6 million to $69.6 million in the aggregate, based on its estimated net cash immediately prior to the closing of its merger with Jade Biosciences, which was announced on October 30, 2024.Merger Status: The Merger remains subject to approval by Aerovate’s stockholders and other closing conditions. The special meeting for stockholder approval is scheduled for April 16, 2025, with the Closing expected on or about April 28, 2025.Dividend Declaration: The official declaration of the Cash Dividend is subject to approval by the Aerovate board of directors and is expected to be announced later this month.Payment Details: The dividend will be paid with an estimated $2.40 per share based on 28,985,019 shares outstanding as of April 9, 2025. The payment date is scheduled for April 29, 2025.Purpose of Merger: The merger will combine Aerovate’s expertise in rare cardiopulmonary diseases with Jade’s focus on developing best-in-class therapies for autoimmune diseases. This combination is expected to create a robust pipeline and enhanced capabilities to address critical unmet medical needs.Stock Performance:Aerovate Therapeutics has exhibited extraordinary performance, with a week-over-week gain of 2914.67% and a month-over-month gain of 2975.95%, making it a standout performer among the stocks listed.<h3>Conclusion</h3>As we conclude our review of these promising companies, it’s clear that these stocks making moves on market news are not just fleeting trends but represent substantial investment opportunities. Each company discussed here is leveraging cutting-edge technology, strategic partnerships, and market shifts to propel their businesses forward, making them standout choices for discerning investors.&nbsp; &nbsp;Read Next: <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/featured/top-4-stocks-poised-for-big-gains/">4 Stocks Poised for Big Gains Amid Major Transformations</a> &nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/newsletter-sign-up/">Our email list eats first! Get exclusive alerts on explosive stock picks like AST SpaceMobile (NASDAQ: ASTS), which shot up +533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.</a><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/groups/WealthyVC">Join the Discussion in the WVC Facebook Investor Group</a>Do you have a stock tip or news story suggestion? Please email us at&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="mailto:Invest@WealthyVC.com">Invest@WealthyVC.com</a>.Disclaimer: Wealthy VC does not hold a position in any of the stocks, ETFs or cryptocurrencies mentioned in this article.

Small Cap News Movers: Your Daily Digest of Stocks Making Moves on Market News

Others

Perpetua Resources Announces Continued Cooperation with U.S. Antimony

Perpetua Resources Announces Continued Cooperation with U.S. Antimony Perpetua Resources Announces Continued Cooperation with U.S. Antimony PR Newswire BOISE, Idaho, Dec. 9, 2024 U.S. Antimony...

Shares of United States Antimony Corp (UAMY) have rallied over the past week in the wake of escalating US-China trade tensions, reaching a 52-week high on Friday, heating up retail chatter. Earlier this week, China banned the exports of rare minerals, including antimony, gallium, and germanium, to the US, a move that could potentially mean an opportunity for companies like United States Antimony. &nbsp; Antimony is a scarce commodity, and United States Antimony sees ongoing supply issues and trade restrictions and resulting worldwide antimony metal prices as an opportunity for the company. It said in a recent release that market prices of the precious metal increased from $5.31 per pound on December 31, 2023 to about $17 per pound as of November 8. Rare minerals are also widely used in the industrial sector United States Antimony recently reported its third-quarter results, which saw its revenues rise 17% to $2.421 million and its gross profit increase 65% to $426,000.&nbsp; Loss from continuing operations was $683,000 for the quarter, up from $185,000 in the same period last year. The rise was “directly related” to the company's expanded scope of operations. Retail sentiment around the stock has turned bullish. Many Stocktwits users were optimistic about the company's prospects, given the application of the rare minerals. <stembedurl>https://stocktwits.com/theleftnutt/message/595451429</stembedurl><stembedurl>https://stocktwits.com/algo888/message/595444278</stembedurl> China’s decision to ban exports appeared to be in reaction to the U.S. curbing exports to 140 companies earlier this week. United States Antimony is up 602% year-to-date. &nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail sentiment around the stock has turned bullish| Image source: WIkimedia Commons

United States Antimony Stock Rallies On Potential Opportunity From China Precious Metals Ban: Retail Bullish

Retail sentiment on the stock has turned bullish. 

U.S. Antimony (UAMY) Announces Plan to Discontinue Latin America Operational Activities

THOMPSON FALLS, MT / ACCESSWIRE / March 11, 2024 / United States Antimony Corporation ('USAC' or 'U.S. Antimony' or the 'Company'), (NYSE:UAMY) announces plan to discontinue all Latin America...

USAC Announces Appointment of Jeffrey Fink as Vice President & General Manager of Bear River Zeolite ("BRZ")

THOMPSON FALLS, MT / ACCESSWIRE / January 29, 2024 / United States Antimony Corporation ('USAC'), (NYSE:UAMY) is pleased to announce the appointment of Jeffrey Fink, age 39, as Vice President and...

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

Will Costco Wholesale ($COST) beat its quarterly EPS estimate? 
 
*Powered by Polymarket

UAMY
United States Antimony Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest UAMY News

UAMY United States Antimony Corp